U.K. Regulatory Advisor Rejects Roche Cancer Drug
Roche Holdings (OTC: RHHBY) has suffered a sales setback for a drug in its cancer portfolio. On Wednesday, the U.K.'s National Institute for Health and Care Excellence (NICE) published an appraisal of Polivy (polatuzumab vedotin) in which it chose not to recommend that the country's National Health Service prescribe the treatment.
NICE is the highly influential advisory arm of the U.K. government's Department of Health.
Image source: Getty Images
Source Fool.com
